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administrative cost database. Clinical validation of the al-
gorithm is warranted.
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OBJECTIVES: The total economic impact of type 2 diabe-
tes in Germany is widely unknown and underestimated
since its complications are often not taken into account.
The pan-European cost of illness study (CODE-2: Costs of
Diabetes in Europe, Type 2) aimed at measuring the total
cost of patients with type 2 diabetes including both costs
of management and complications.
METHODS: For Germany, a bottom-up, prevalence-
based design was used to collect data on resource utilisa-
tion of 809 patients with diabetes type 2 for the year 1998.
A representative random sample of 135 office-based physi-
cians (GPs and specialists) provided data using patients’
medical records in face-to-face interviews. For the extrapo-
lation on a population level, costs were weighted accord-
ing to prevalence data on complications derived from an
epidemiological pre-study. Data were analysed from a so-
cietal perspective.
RESULTS: Total direct medical costs per patient per year
were on average DM 7,012, ranging from DM 156 to DM
137,512. The main part of the costs (61%) was induced
by hospitalisations and long-term care. Observed costs per
treatment type were DM 5,890 for diet, DM 5,621 for
OAD and DM 9,799 for insulin-treated patients. The
analysis per complication status showed a range from DM
3,716 for patients without, and up to DM 13,283 for pa-
tients with both micro- and macrovascular complications.
Assuming a diabetes type 2 prevalence of 4.24%, the total
annual direct costs for the respective population were esti-
mated to be DM 24,388 million.
CONCLUSIONS: The data substantiate the enormous so-
cio-economic burden and that costs are much higher than
estimated in previous studies. Treatment costs of diabetes
show a broad variance. Costs increase with age and are
highly related to occurrence of complications and onset of
insulin treatment. Furthermore, the study highlights that
costs are directly related to the severity of the patient’s ill-
ness.
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OBJECTIVES: Underlying the success of multi-country
cost of illness studies are the methods used to identify, enu-
merate and value the resources that constitute the overall
costs of the disease being studied. The design objective of
the data collection instruments is to ensure consistency be-
tween countries and retrieval of all relevant data.
METHODS: The CODE-2* (Costs of Diabetes in Europe
type 2) study is a bottom-up, prevalence based cost of ill-
ness study conducted to evaluate the total burden of type 2
diabetes in 8 European countries. The objective of the
study was to fully identify all costs relating to the manage-
ment of the disease and its associated complications in ad-
dition to patient demographic and clinical parameters.
Data for over 7000 patients were collected retrospectively
over a 6-month period from a variety of sources including
patient interviews, medical records and registries. This re-
quired the design of common data collection tools that
could be used in all eight countries by over 600 practitio-
ners included in the study. Identification of core items of
resource utilisation and clinical assessments was done in
consultation with European and national advisory boards
consisting of health economists, clinicians and healthcare
researchers. A process of forward and back translation en-
sured the cultural and linguistic integrity of the eight lan-
guage versions used. Layout and instrument design were
developed by iteration between the central study coordi-
nating and country teams and assessed by mini-pilots. Fi-
nal field tests ensured acceptability and suitability for
study participants.
RESULTS: The resulting country specific practitioner and
patient data collection instruments were consistent in all
aspects for core resource utilisation items necessary for in-
ter-country comparison of the study results.
CONCLUSION: The instruments and development pro-
cess used for the CODE-2 study should serve as a model
for other multi-country cost of illness studies. *Registered
Trademark of SmithKline Beecham
PEN6
COSTS OF TREATING NAIVE PATIENTS WITH 
TYPE 2 DIABETES—A COMPARISON BETWEEN 
THE UNITED KINGDOM AND FRANCE
Pashos CL, Tafesse E, Botteman M
Abt Associates Clinical Trials, Cambridge, MA, USA
OBJECTIVES: To estimate for the United Kingdom (UK)
and France the first year diabetes-related costs of naive pa-
tients with type 2 diabetes initiated upon therapy with the
same oral hypoglycemic agent (Diamicron). In both the
UK and France, responsibility for the care of patients with
type 2 diabetes rests with general practitioner physicians.
METHODS: Patient records of consecutive naive patients
were collected from general practices (two in the UK, one in
France). Diabetes-related resource utilization and costs for
the first year post-initiation of oral therapy were analyzed.
This included medication, professional visits, hospital out-
patient visits, emergency visits, inpatient hospitalizations,
laboratory tests and procedures, and self-administered tests.
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RESULTS: Healthcare utilization and concomitant costs
(denominated in the Euro) for naive type 2 diabetic patients
initiated on Diamicron varied greatly between these prac-
tices in the UK and France. The biggest difference in utiliza-
tion was greater use in France of hospital inpatient and hos-
pital outpatient services. Total annual direct medical costs
in France were approximately 1,620 Euro (10,600FF), com-
pared with 454 Euro (320 BP) in the UK. Costs of Diami-
cron, as actually prescribed and used by the patients, also
varied considerably: 112 Euro in France versus 65 Euro in
the UK.
CONCLUSION: Patient care and associated costs for pa-
tients newly diagnosed with a common clinical condition
such as diabetes can vary considerably even within popu-
lous western European nations. Analyses of cost of illness
and cost effectiveness must be careful to use country-spe-
cific data in order to maximize the utility of these analyses
by relevant decision-makers within those countries.
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OBJECTIVE: To offer direct cost estimates of patients with
diabetes mellitus based on retrospectively collected data.
METHODS: A multicenter, retrospective observational
study on 30 diabetic centres located in 12 different re-
gions of Italy. Each diabetes centre randomly selected be-
tween 60 and 100 patients with diabetes mellitus. A total
of 2,135 patients were enrolled. For each patient data on
resource consumption was collected retrospectively—on
the two months preceding the enrolment—using a ques-
tionnaire filled in by physicians of the participant centres.
Per patient-year direct cost estimates were produced, tak-
ing the Italian National Health Service (INHS) perspec-
tive, by linking per patient service use data with INHS
tariffs of day-hospital admissions, outpatient visits, labo-
ratory and diagnostic tests, and drug prices. Drug cost
was calculated by multiplying the daily dose by the pub-
lic price when taken at home, and by 50% of the public
price when taken in hospital and ambulatory setting.
RESULTS: Total direct medical cost per patient was on av-
erage Italian L. 1,708,364 for Type I diabetes (N  572;
mean age 51.7) and L. 1,623,728 for Type II diabetes (N 
1,563; mean age 61.4). Drugs accounted for 32% of the
total cost in Type I patients and 17% in Type II, while out-
patient care, day-hospital admissions included, accounted
for 68% and 83%. Inpatient costs were not included.
CONCLUSION: This study suffers some major limits. Only
patients, and not centres, were randomly selected; resource
use data was retrospectively collected over two months of
observations, and unit costs were based on INHS tariffs.
However, since in Italy the cost of diabetes has received lim-
ited attention, we believe this study presents some interest-
ing information on the burden of diabetes in this country.
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OBJECTIVES: As part of a pan-European cost of illness
study in eight countries (CODE-2*: Costs of Diabetes in
Europe, Type 2) the CODE-2* UK objective was to mea-
sure cost of care for patients with type 2 diabetes (T2D) in
terms of management and complication costs in the UK.
METHODS: This was a bottom-up, prevalence-based
study design, which collected resource use and clinical out-
come data across primary and secondary care. Data
sources include comprehensive population-based diabetes
registers (the ‘primary databases’) and hospital and pri-
mary care records (‘secondary databases’). 756 T2D pa-
tients (defined as aged 30 or above at diagnosis) were iden-
tified from 3 registers. Clinical data was reviewed against
treatment guidelines to assess status of T2D management.
Preliminary results based on data in the 6-month period
July 1st to December 31st 1998 were analyzed first.
RESULTS: Assuming a UK prevalence of T2D of 2% the
total direct medical costs for people with T2D in the UK in
1998 were estimated to be £1.83 billion or 3.4% of health-
care expenditure. Average costs for patients with T2D were
£1550 per year. The costs attributed to oral anti-diabetic
drugs comprised 2.7% of overall direct costs. Costs for pa-
tients with T2D with microvascular and macrovascular
complications with indicators of Insulin Resistance Syn-
drome were higher than for patients without complica-
tions. The proportion of patients achieving good glycemic
control (6.5% HBA1c) decreased as patients progressed
from diet and exercise through to insulin alone or in com-
bination, highlighting the progressively increasing need for
treatment as duration of disease increases.
CONCLUSIONS: CODE-2* UK provides evidence of di-
rect costs and management of T2D in the NHS. It is a rich
data set to inform Health Boards, Health Authorities and
Primary Care Groups of how costs are composed and the
likely outcomes seen for T2D management. *Trademark
of SmithKline Beecham plc.
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ABSTRACT OBJECTIVE: To develop a pharmacody-
namic-pharmacoeconomic model to compare effectiveness
and costs of anti-inflammatory therapies used in asthma
treatment.
